BMC Nephrology最新文献

{"title":"Carotid intima-media thickness, fibroblast growth factor 23, and mineral bone disorder in children with chronic kidney disease. Knowing the limitations of the applied methodology for a better understanding of the clinical results.","authors":"Christian Saleh","doi":"10.1186/s12882-025-04017-2","DOIUrl":"10.1186/s12882-025-04017-2","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"89"},"PeriodicalIF":2.2,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health professional experiences of kidney transplantation in regional, rural, and remote Australia.","authors":"Tara K Watters, Beverley D Glass, Nicole J Scholes-Robertson, Andrew J Mallett","doi":"10.1186/s12882-025-04015-4","DOIUrl":"10.1186/s12882-025-04015-4","url":null,"abstract":"<p><strong>Background: </strong>Despite the demonstrated improved patient survival and financial benefits for health services with kidney transplantation compared to dialysis, populations outside of urban areas face inequities in access and a more difficult journey to kidney transplantation than their metropolitan counterparts. This study aimed to explore the experiences of Australian kidney transplant health professionals regarding kidney transplantation processes for patients residing in regional, rural, and remote areas, with a focus on improving access to and experiences of transplantation for this patient cohort.</p><p><strong>Methods: </strong>Semi-structured interviews were conducted with Australian kidney transplant health professionals. Transcripts were analysed thematically.</p><p><strong>Results: </strong>Interview participants (n = 26) consisted primarily of nephrologists from transplanting centres (15%), nephrologists from regional, rural, or remote non-transplanting centres (19%), clinical pharmacists (19%), and nursing staff (19%). Six main themes were identified regarding barriers to transplantation, including ineffective communication and education, overwhelming geographical burden, fighting for equal opportunities, paucity of social support, crushing financial peril, and deprived of adequate local care. Participants also made recommendations for new or modified service delivery models to address identified barriers, including coordination of work-up testing, outreach visits for transplant assessment, increased social and financial support, and increased and earlier provision of transplant education.</p><p><strong>Conclusions: </strong>Health professionals described patient-specific and system level barriers to kidney transplantation for regional, rural, and remote populations in Australia that could be addressed or improved by the modification of current processes or implementation of new service delivery models for provision of transplant care.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"88"},"PeriodicalIF":2.2,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indications and complications associated with centrifuge-based therapeutic plasma exchange - a retrospective review.","authors":"David Warner, Heather Duncan, Prakash Gudsoorkar, Manish Anand","doi":"10.1186/s12882-025-03970-2","DOIUrl":"10.1186/s12882-025-03970-2","url":null,"abstract":"<p><strong>Background: </strong>Therapeutic Plasma Exchange (TPE) is an extracorporeal treatment modality used to manage certain conditions caused by plasma deficiencies, autoantibodies, alloantibodies, toxins, and immune complexes. We describe our experience of using TPE for various disease indications and associated complications.</p><p><strong>Methods: </strong>This is a retrospective, single-center review of centrifuge-based TPE performed by the division of nephrology at a tertiary care academic center between July 2018 to June 2022. 1219 TPE treatments in 145 patients were included.</p><p><strong>Results: </strong>The most common indications for TPE were Antibody-Mediated Rejection (AMR) of a kidney transplant (20%), autoimmune encephalitis (16%), and neuromyelitis optica (11%). Rare indications for TPE included Chronic Relapsing Inflammatory Optic Neuropathy (CRION), AMR of a pancreas transplant, osmotic demyelination, and belatacept removal in the setting of COVID-19. The most common complications were depletion coagulopathy (47.6%), hypocalcemia (44.1%), and hypokalemia (36.6%). Rare complications included stiff person crisis and pseudohypertriglyceridemia. 31.7% of patients received TPE for conditions managed by nephrologists.</p><p><strong>Conclusion: </strong>TPE is an extracorporeal treatment modality for managing various renal and non-renal diseases. The study demonstrated that 18.7% of the patients at our center received TPE for conditions in which its role is not yet established, suggesting the need for further research on the use of TPE. In addition, this study supports the necessity of nephrology training program to include education on TPE as almost one-third of the indications for TPE in our center were for conditions managed by nephrologists.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"87"},"PeriodicalIF":2.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of neuromuscular electrical stimulation during hemodialysis on muscle strength, functional capacity and postural balance in patients with end-stage renal disease: a randomized controlled trial.","authors":"Amal Machfer, Nadia Fekih, Achraf Ammar, Hayfa Ben Haj Hassen, Wael Daab, Hassen Ibn Hadj Amor, Mohamed Amine Bouzid, Hamdi Chtourou","doi":"10.1186/s12882-025-03994-8","DOIUrl":"10.1186/s12882-025-03994-8","url":null,"abstract":"<p><strong>Background: </strong>Hemodialysis patients (HD) have a limited physical capacity and this often means low adherence to rehabilitation programs based on conventional exercise. This study investigated the effectiveness of neuromuscular electrical stimulation (NMES) during HD therapy on muscle strength, functional capacity and postural balance in HD patients.</p><p><strong>Methods: </strong>Twenty-two HD patients were randomly assigned to a control group (CG) or a neuromuscular electrical stimulation training group (NSTG). The NSTG underwent NMES on the quadriceps muscle during HD sessions for 12 weeks, three times per week (40 min per session. Center of pressure (COP) displacement in the mediolateral direction (COPx), in the anteroposterior direction (COPy), and the COP area (COP area) were recorded using a stabilometric platform. Timed Up and Go test (TUG) and Sit to Stand (STS30) tests, 6-minute walking test (6MWT), and the maximal voluntary contraction (MVC) were measured before and after the intervention in both groups.</p><p><strong>Results: </strong>There was a significant increase in MVC (+ 24.5%; P < 0.01), 6MWT (+ 9.8%; P < 0.05) and STS30 (+ 25.6%; P < 0.01) performance in the NSTG following the NMES intervention period. A significant reduction was observed in TUG (-11.8%; P < 0.01), COPx(-20.1%; P < 0.05) and COPy (-24.7%; P < 0.01) following the intervention period only in the NSTG. However, no significant changes were observed in the CG following the intervention period.</p><p><strong>Conclusion: </strong>This study supports the effectiveness of intradialytic NMES to improve muscular strength, functional capacity and postural balance in HD patients. Given the limited implementation of exercise programs in dialysis clinical practice, NMES during HD sessions offers a novel therapeutic alternative to enhance physical condition and quality of life in these patients.</p><p><strong>Trial registration: </strong>Pan African Clinical Trial Registry Identifer: PACTR202206634181851 Registered on 21/06/2022. Registered trial name: Beneficial Effect of Intradialytic Electrical Muscle Stimulation in Hemodialysis Patients.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"86"},"PeriodicalIF":2.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bio-sociological and clinical factors of chronic pain and pain interference in patients undergoing hemodialysis: a cross-sectional study.","authors":"Fatima Z Bouchachi, Nadia Al Wachami, Younes Iderdar, Maryem Arraji, Abdeljalil Elgot, Mohamed Chahboune","doi":"10.1186/s12882-025-03987-7","DOIUrl":"10.1186/s12882-025-03987-7","url":null,"abstract":"<p><strong>Background: </strong>End-stage kidney disease is an irreversible and incurable alteration of kidney function, requiring renal replacement therapy such as hemodialysis. Hemodialysis patients are one of the most symptomatic of all chronic kidney disease groups, including chronic pain. Overlooked, underestimated, and undermanaged, pain is associated with altered health-related quality of life. Therefore, this study aims to explore the biological, clinical, and social variables associated with chronic pain and its interference with hemodialysis patients.</p><p><strong>Methods: </strong>A cross-sectional study was conducted on Moroccan hemodialysis patients. A total of 307 patients participated in the study. Data collection was based on a structured questionnaire with sociodemographic, clinical, and dialysis variables. The Numeric Rating Scale and Brief Pain Inventory were used to assess pain characteristics.</p><p><strong>Results: </strong>Almost half of the hemodialysis had chronic pain, the mean pain severity and pain interference scores were 3.73 ± 3.59, and 22.89 ± 22.74 respectively. Multiple regression analysis revealed that gender (p = 0.022), number of comorbidities (p = 0.001), dialysis vintage (p < 0.001), number of pain sites (p < 0.001), and PTH level (p < 0.001) were associated with pain severity score. Older patients (p = 0.049), gender (p = 0.007), subjects with a number of comorbidities (p < 0.001), dialysis vintage (p < 0.001), number of pain sites (p < 0.001), and level of PTH (p < 0.001) were significantly associated with pain interference score.</p><p><strong>Conclusions: </strong>The subgroups with increased pain severity were female hemodialysis, subjects living with multiple comorbid conditions, those with length dialysis vintage, a high number of painful sites, and increased PTH levels. Assessing and reducing pain intensity, pain interference, and its factors must be a priority for healthcare providers to manage pain and improve health-related quality of life.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"83"},"PeriodicalIF":2.2,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C3 glomerulopathy associated with mycoplasma pneumoniae infection and positive IgA staining.","authors":"Zhi-Yu Duan, Ji-Jun Li, Guang-Yan Cai, SuXia Wang, XuanLi Tang, WanYin Hou, Lei Jiang, Yan Song","doi":"10.1186/s12882-025-04010-9","DOIUrl":"10.1186/s12882-025-04010-9","url":null,"abstract":"<p><strong>Background: </strong>Patients with C3 glomerulopathy (C3G) often have a history of infection, which implies that infection may lead to abnormal activation of the complement alternative pathway (CAP) and induce the development of C3G. However, patients with postinfectious glomerulonephritis (PIGN) often have a low serum C3 concentration and positive glomerular C3 staining, consistent with the activation of the CAP. PIGN, especially if it involves simultaneous IgA deposition, is often difficult to differentiate from C3G.</p><p><strong>Case presentation: </strong>In this study, we report the consequences of Mycoplasma pneumoniae (MP) infection in a 66-year-old male Chinese patient, who developed persistent hypocomplementemia, gross hematuria, and rapidly progressive glomerulonephritis. The findings of the histologic examination of an initial renal biopsy were consistent with a diagnosis of IgA-dominant postinfectious glomerulonephritis. The sample was negative for Gd-IgA1 staining. After treatment with antibiotics, glucocorticoids, and mycophenolate mofetil, the patient's serum creatinine decreased from a peak of 387 µmol/L to 195 µmol/L prior to discharge, and there was a partial response in his urinary protein concentration. After 2 months, his serum C3 concentration had returned to normal. However, owing to reinfection with MP the patient's serum creatinine rapidly increased again to 475.07 µmol/L, and this was accompanied by a decrease in serum C3 concentration (> 8 months) and positivity for C3 nephritis factor. Examination of both renal biopsies showed stronger immunostaining for C3 than for IgA in the glomeruli.</p><p><strong>Conclusion: </strong>Thus, MP infection can cause sustained activation of the CAP, leading to C3G. For patients with MP infection, if there is an ongoing decrease in complement C3 levels and a progressive increase in serum creatinine, it is crucial to be vigilant for possible C3G and to consider the use of immunosuppressive therapy in conjunction with anti-infective treatment to prevent the ongoing activation of the CAP.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"85"},"PeriodicalIF":2.2,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of obstetric versus non-obstetric acute kidney injury: insights from an Indian tertiary care centre.","authors":"Beauty Suman, Lalit Pursnani, Himansu Sekhar Mahapatra, Ashok Kumar, B Muthukumar, Renju Binoy, Tanvi Thakker, Mahboob Alam, Abhishek Jha","doi":"10.1186/s12882-025-04001-w","DOIUrl":"10.1186/s12882-025-04001-w","url":null,"abstract":"<p><strong>Background: </strong>Pregnancy-related Acute kidney injury (PR-AKI) accounts for approximately 15% of maternal mortality, with 10-30% progressing to end stage renal disease (ESRD). However, there are no comparative studies of obstetric and non-obstetric AKI. This study compares the outcomes of both groups with short-term follow-up to day 90.</p><p><strong>Materials and methods: </strong>This prospective observational study was conducted over 1.5 years, enrolling 260 cases divided into non-obstetric and obstetric AKI groups.</p><p><strong>Inclusion criteria: </strong>Non-obstetric group - patients > 18 years with AKI; Obstetric group - pregnant or up to 42 days postpartum with AKI, as per KDIGO criteria. Patients with known Chronic kidney disease (CKD) or transplant were excluded. Demographics, clinical profiles and relevant investigations (including renal biopsy) were analysed. Outcomes assessed at days 7, 30, and 90 for complete recovery, dialysis dependency, CKD progression, and mortality.</p><p><strong>Results: </strong>Of 260 patients, 83.4% were in non-obstetric group while 16.6% were in the obstetric group. Sepsis was leading cause of AKI (51.5%), affecting 47.7% of non-obstetric and 74.4% of obstetric patients. Renal biopsies (12.3% of cases) predominantly showed acute tubular injury, lupus nephritis, Minimal change disease, Focal segmental glomerulosclerosis, ANCA-associated Glomerulonephritis (GN), IgA nephropathy, and Membranoproliferative GN. In Obstetric AKI, acute cortical necrosis and thrombotic microangiopathy (TMA) were common biopsy findings. At 3-months follow-up, complete recovery was higher in the non-obstetric group (40.5% vs. 33.3%), with the obstetric group having more progression to CKD and dialysis dependency. Mortality was higher in non-obstetric AKI (50.4% vs. 33.3%), likely due to underlying comorbidities.</p><p><strong>Conclusion: </strong>Non-obstetric AKI showed higher early mortality but better long-term recovery, while obstetric AKI had poorer renal outcomes and a higher risk of progression to CKD. Early detection and intervention are critical for improving outcomes.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"84"},"PeriodicalIF":2.2,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837580/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research on the development of an intelligent prediction model for blood pressure variability during hemodialysis.","authors":"Zhijian Ren, Minqiao Zhang, Pingping Wang, Kanan Chen, Jing Wang, Lingping Wu, Yue Hong, Yihui Qu, Qun Luo, Kedan Cai","doi":"10.1186/s12882-025-03959-x","DOIUrl":"10.1186/s12882-025-03959-x","url":null,"abstract":"<p><strong>Objective: </strong>Blood pressure fluctuations during dialysis, including intradialytic hypotension (IDH) and intradialytic hypertension (IDHTN), are common complications among patients undergoing maintenance hemodialysis. Early prediction of IDH and IDHTN can help reduce the occurrence of these fluctuations. With the development of artificial intelligence, machine learning and deep learning models have become increasingly sophisticated in the field of hemodialysis. Utilizing machine learning to predict blood pressure fluctuations during dialysis has become a viable predictive method.</p><p><strong>Methods: </strong>Our study included data from 67,524 hemodialysis sessions conducted at Ningbo No.2 Hospital and Xiangshan First People's Hospital from August 1, 2019, to September 30, 2023. 47,053 sessions were used for model training and testing, while 20,471 sessions were used for external validation. We collected 45 features, including general information, vital signs, blood routine, blood biochemistry, and other relevant data. Data not meeting the inclusion criteria were excluded, and feature engineering was performed. The definitions of IDH and IDHTN were clarified, and 10 machine learning algorithms were used to build the models. For model development, the dialysis data were randomly split into a training set (80%) and a testing set (20%). To evaluate model performance, six metrics were used: accuracy, precision, recall, F1 score, ROC-AUC, and PR-AUC. Shapley Additive Explanation (SHAP) method was employed to identify eight key features, which were used to develop a clinical application utilizing the Streamlit framework.</p><p><strong>Results: </strong>Statistical analysis showed that IDH occurred in 56.63% of hemodialysis sessions, while the incidence of IDHTN was 23.53%. Multiple machine learning models (e.g., CatBoost, RF) were developed to predict IDH and IDHTN events. XGBoost performed the best, achieving ROC-AUC scores of 0.89 for both IDH and IDHTN in internal validation, with PR-AUC scores of 0.95 and 0.78, and high accuracy, precision, recall, and F1 scores. The SHAP method identified pre-dialysis systolic blood pressure, BMI, and pre-dialysis mean arterial pressure as the top three important features. It has been translated into a convenient application for use in clinical settings.</p><p><strong>Conclusion: </strong>Using machine learning models to predict IDH and IDHTN during hemodialysis is feasible and provides clinically reliable predictive performance. This can help timely implement interventions during hemodialysis to prevent problems, reduce blood pressure fluctuations during dialysis, and improve patient outcomes.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"82"},"PeriodicalIF":2.2,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143439821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update.","authors":"Matt Gittus, Helen Haley, Tess Harris, Sarah Borrows, Neal Padmanabhan, Danny Gale, Roslyn Simms, Terri Williams, Aaron Acquaye, Alisa Wong, Melanie Chan, Eduardo Lee, Albert Cm Ong","doi":"10.1186/s12882-025-03960-4","DOIUrl":"10.1186/s12882-025-03960-4","url":null,"abstract":"<p><p>Autosomal Dominant Polycystic Kidney Disease (ADPKD) affects up to 70 000 people in the UK and the most common inherited cause of end-stage kidney disease (ESKD). It is generally a late-onset multisystem disorder characterised by bilateral kidney cysts, liver cysts and an increased risk of intracranial aneurysms. Approximately 50% of people with ADPKD reach ESKD by age 60. Disease-associated pain, discomfort, fatigue, emotional distress and, impaired mobility can impact health-related quality of life. The approval of tolvaptan, a vasopressin V2 receptor antagonist, has greatly advanced the care for people with ADPKD, shifting the focus from general chronic kidney disease management to targeted therapeutic approaches. While guidance from NICE and SMC provides a foundational framework, this is not clear or comprehensive enough to offer practical guidance for healthcare professionals in real-world settings. This commentary expands on the previous United Kingdom Kidney Association (UKKA) commentary in 2016 with an updated evidence base, the incorporation of real-world data and expert opinion to provide practical guidance to healthcare professionals. Through co-development with people affected by ADPKD, it now incorporates valuable patient perspectives and offers practical recommendations for the UK kidney community seeking to harmonise the quality of care of all people with ADPKD.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"79"},"PeriodicalIF":2.2,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Membranoproliferative glomerulonephritis with syphilis involvement and possible Hepatitis B virus contribution: a case report.","authors":"Yan Pan, Jiqiang Zhang, Lei Liu, Ruiping Zhao, Tiekun Li, Weidong Chen","doi":"10.1186/s12882-025-03998-4","DOIUrl":"10.1186/s12882-025-03998-4","url":null,"abstract":"<p><strong>Background: </strong>Syphilis, a sexually transmitted disease, presents with a wide range of clinical manifestations. As the global rate of syphilis infection continues to rise, so does the incidence of syphilis-associated nephritis. Characterized by diverse clinical and pathological features, the disease shows a good response to penicillin treatment. This article presents the case of a 46-year-old Chinese male patient exhibiting edema, hematuria, proteinuria, and a tendency towards rapidly progressive glomerulonephritis (RPGN). The patient was diagnosed with membranoproliferative glomerulonephritis (MPGN), with syphilis being a likely etiology and co-infection with Hepatitis B virus (HBV). He was treated with benzathine penicillin for three weeks, followed by low-dose glucocorticoids and mycophenolate mofetil (MMF) for subsequent treatment, leading to a significant improvement in his condition.</p><p><strong>Conclusion: </strong>Highlighting the significance of syphilis as a cause of nephritis and emphasizing the importance of timely diagnosis and treatment can greatly alleviate the patient's condition. Additionally, the role of Hepatitis B virus as a contributing factor in the development of nephritis should not be overlooked.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"80"},"PeriodicalIF":2.2,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}